Detalhe da pesquisa
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer
; 154(6): 1043-1056, 2024 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37994647
2.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37789669
3.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int
; 44(5): 1108-1125, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38517286
4.
Management of hepatocellular carcinoma, an important cause of death in Japanese autoimmune hepatitis patients.
BMC Gastroenterol
; 24(1): 123, 2024 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38561671
5.
Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.
Hepatol Res
; 2024 Apr 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38685853
6.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-37983642
7.
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Oncology
; 101(9): 542-552, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37552968
8.
Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab.
Oncology
; 101(4): 270-282, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36455517
9.
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
Oncology
; 101(10): 624-633, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37307798
10.
Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.
Oncology
; 101(5): 283-291, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36657420
11.
Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.
Hepatol Res
; 53(2): 172-178, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36214071
12.
Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: A retrospective, multicenter study.
Hepatol Res
; 53(1): 51-60, 2023 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-36136893
13.
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Hepatol Res
; 53(10): 1031-1042, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37306040
14.
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatol Res
; 53(8): 737-748, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37020416
15.
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
J Gastroenterol Hepatol
; 38(8): 1389-1397, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37231943
16.
Galectin-9 in Gastroenterological Cancer.
Int J Mol Sci
; 24(7)2023 Mar 24.
Artigo
Inglês
| MEDLINE | ID: mdl-37047155
17.
MicroRNAs and Nonalcoholic Steatohepatitis: A Review.
Int J Mol Sci
; 24(19)2023 Sep 23.
Artigo
Inglês
| MEDLINE | ID: mdl-37833930
18.
Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
Oncology
; 100(12): 645-654, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36103846
19.
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice.
Hepatol Res
; 52(9): 773-783, 2022 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-35633504
20.
Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
Hepatol Res
; 52(3): 235-246, 2022 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-34861090